SONN Research and Charts

SONN - Sonnet BioTherapeutics Holdings Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-10-27)

Last 5.85	Change ⇑ +2.22 (+61.16%)	Volume 1,051,243
	Open 5.21	High 5.85	Low 5.03

8EMA (Daily) 4.41	40EMA (Daily) 4.54	50EMA (Daily) 4.45	STO (Daily) 27.449	MACD Hist (Daily) 0.112
8EMA (Weekly) 4.637	40EMA (Weekly) 4.36	50EMA (Weekly) 7.09	STO (Weekly) 25.950	MACD Hist (Weekly) -0.058


Company Profile
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.